Expert consensus on perioperative treatment for non-small cell lung cancer.

Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-22-527/coif). CZ serves as an Editor-in-Chief of Translational Lung Cancer Research from August 2014 to July 2022. SHL serves as an unpaid editorial board member of Translational Lung Cancer Research from September 2019 to September 2023. GM serves as an unpaid editorial board member of Translational Lung Cancer Research from February 2016 to July 2023. CG serves as an unpaid editorial board member of Translational Lung Cancer Research from September 2019 to September 2023, and received honoraria as speaker bureau or advisory board member or consulting fees form Menarini, Roche, Eli Lilly, Boehringer, Amgen, Pfizer, Novartis, MSD, BMS, Astra Zeneca, Takeda, Novartis, GSK, Karyopharm. Qing Z received lecture and presentations fees from AstraZeneca, Boehringer Ingelheim, BMS, Eli Lilly, MSD, Pfizer, Roche, and Sanofi. AB received consulting fees as an Advisory Board with Astra Zeneca, BD, Ethicon, Medtronic, Roche, and is the president of European Society of Thoracic Surgeons. TJ received consulting fees from Roche, Merck, MSD, Puma, AstraZeneca, BMS, Amgen, Gilead, Specialised Therapeutics. DHO reports research funding (to institution) from Genentech, BMS, Merck, Pfizer, Palobiofarma, and Onc. AI. MR received honoraria for lectures and expert meetings from Astrazeneca, and also received honoraria for lectures and expert meetings as well as travel expenses from Abex. KS received a research grant from Boehringer-Ingelheim, through Kindai University Faculty of Medicine, has received consulting fees from AstraZeneca, and has received honoraria from Chugai, Taiho, and AstraZeneca. FT received speaker bureau from AstraZeneca. The other authors have no conflicts of interest to declare.